Biocon partner Fujifilm launches its insulin glargine in Japan
India’s leading biotech firm Biocon (BSE: 53252) says that, close on the heels of receiving approval for its insulin glargine from the Japanese regulator last quarter, its partner Fujifilm Pharma (FFP) has now launched the product in Japan.
Insulin glargine BS injection kit has been developed and manufactured by Biocon, and is being commercialized by FFP in Japan. The product is a ready-to-use, prefilled disposable pen with 3ml of 100IU insulin glargine. It will provide a high quality, yet affordable, world-class long-acting biosimilar to French pharma major Sanofi’s (Euronext: SAN) blockbuster band Lantus for diabetes patients in Japan. There were 7.2 million people with diabetes in Japan in 2015, according to the International Diabetes Federation.
Aims for significant share of $144 million Japanese glargine market
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze